TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence

Cell Cycle

Volumn 12, Issue 3, 2013, Pages 511-521

  Chefetz, Ilana ^a   Alvero, Ayesha B ^a   Holmberg, Jennie C ^a   Lebowitz, Noah ^a   Craveiro, Vinicius ^a   Yang Hartwich, Yang ^a   Yin, Gang ^a   Squillace, Lisa ^a   Soteras, Marta Gurrea ^a   Aldo, Paulomi ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ovarian cancer stem cells; Recurrence; Self renewal; TLR2; Tumor repair

Indexed keywords

HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; TOLL LIKE RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURGERY; CELL RENEWAL; CONTROLLED STUDY; GENETIC ASSOCIATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84875429906     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.23406     Document Type: Article

References (59)

1. Silasi DA, Illuzzi JL, Kelly MG, Rutherford TJ, Mor G, Azodi M, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008; 18: 22-9; PMID:17451459; http://dx.doi.org/10.1111/j.1525-1438.2007.00948.x
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
3. Baker TR, Piver MS, Hempling RE. Response to Taxol chemotherapy in resistant ovarian carcinoma. Eur J Gynaecol Oncol 1993; 14: 449-54; PMID:7910134
4. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7(Suppl 5): 20-8; PMID:12324630; http://dx.doi.org/10.1634/theoncologist.7-suppl-5-20
5. Bast RC Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9: 415-28; PMID:19461667; http://dx.doi.org/10.1038/nrc2644
6. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994; 1: 181-90; PMID:9419769
7. Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J Invest Dermatol 2005; 124:x-xiv; PMID:15955081; http://dx.doi.org/10.1111/j.0022-202X.2005.23724.x
8. Neth P, Ries C, Karow M, Egea V, Ilmer M, Jochum M. The Wnt signal transduction pathway in stem cells and cancer cells: influence on cellular invasion. Stem Cell Rev 2007; 3: 18-29; PMID:17873378; http://dx.doi.org/10. 1007/s12015-007-0001-y
9. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44; PMID:16990346; http://dx.doi.org/10.1158/0008-5472.CAN-06-3126
10. Maitland NJ, Bryce SD, Stower MJ, Collins AT. Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc 2006; 5: 155-79
11. Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int 2005; 96: 1219-23; PMID:16287434; http://dx.doi.org/10. 1111/j.1464-410X.2005.05744.x
12. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11; PMID:11689955; http://dx.doi.org/ 10.1038/35102167
13. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009; 27: 2405-13; PMID:19658191; http://dx.doi.org/10.1002/stem.191
14. Mor G, Yin G, Chefetz I, Yang Y, Alvero A. Ovarian cancer stem cells and inflammation. Cancer Biol Ther 2011; 11: 708-13; PMID:21317559; http://dx.doi.org/10.4161/cbt.11.8.14967
15. Morrison SJ, Kimble j.Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006; 441: 1068-74; PMID:16810241; http://dx.doi.org/10.1038/nature04956
16. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8: 158-66; PMID:19158483; http://dx.doi.org/10.4161/cc.8.1.7533
17. Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G. Distinct Subpopulations of Epithelial Ovarian Cancer Cells Can Differentially Induce Macrophages and T Regulatory Cells Toward a Pro-Tumor Phenotype. Am J Reprod Immunol 2012; 67: 256-65; PMID:21917055; http://dx.doi.org/10.1111/j.1600-0897.2011.01068.x
18. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther 2011; 10: 1385-93; PMID:21677151; http://dx.doi.org/10.1158/1535-7163.MCT-11-0023
19. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65: 3025-9; PMID:15833827
20. Kurrey NK, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97: 155-65; PMID:15790452; http://dx.doi.org/10.1016/j.ygyno.2004.12.043
21. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-20; PMID:18519691; http://dx.doi.org/10.1158/0008-5472.CAN-08-0364
22. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010; 5:e10277; PMID:20422001; http://dx.doi.org/10.1371/journal.pone.0010277
23. Silva IA, Bai S, McLean K, Yang K, Griffith KA, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001; PMID:21498635; http://dx.doi.org/10.1158/0008-5472.CAN-10-3175
24. Dyall S, Gayther SA, Dafou D. Cancer stem cells and epithelial ovarian cancer. J Oncol 2010; 2010:105269; PMID:21318146; http://dx.doi.org/10.1155/ 2010/105269
25. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009; 27: 2405-13; PMID:19658191; http://dx.doi.org/10.1002/stem.191
26. Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, et al. Regulation of inflammation by the NFκB pathway in ovarian cancer stem cells. Am J Reprod Immunol 2011; 65: 438-47; PMID:20825380; http://dx.doi.org/ 10.1111/j.1600-0897.2010.00914.x
27. Steffensen KD, Alvero AB, Yang Y, Waldstrøm M, Hui P, Holmberg JC, et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011; 2011:620523; PMID:21904548; http://dx.doi.org/10.1155/2011/620523
28. Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z. Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol 2009; 33: 175-81; PMID:19728235
29. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 2008; 68: 5658-68; PMID:18632618; http://dx.doi.org/10.1158/0008-5472.CAN-07-6341
30. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006; 103: 11154-9; PMID:16849428; http://dx.doi.org/ 10.1073/pnas.0603672103
31. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27: 2875-83; PMID:19816957
32. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007; 57: 93-107; PMID:17217363; http://dx.doi.org/10.1111/ j.1600-0897.2006.00441.x
33. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med (Berl) 2006; 84: 712-25; PMID:16924467; http://dx.doi.org/10.1007/s00109-006- 0084-y
34. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005; 11: 1173-9; PMID:16244651; http://dx.doi.org/10.1038/nm1315
35. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59; PMID:17979839; http://dx.doi.org/10.1111/j.1600-065X.2007.00573.x
36. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, et al. Regulation of IKKbeta by miR- 199a affects NFkappaB activity in ovarian cancer cells. Oncogene 2008; 27: 4712-23; PMID:18408758; http://dx.doi.org/10.1038/onc. 2008.112
37. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
38. Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 2006; 16: 32-7; PMID:16153858; http://dx.doi.org/10.1016/j.semcancer.2005.07.004
39. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and Paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66: 3859-68; PMID:16585214; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-3948
40. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124: 1111-5; PMID:16564000; http://dx.doi.org/10.1016/j.cell.2006.03.011
41. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 2013; 32: 39-49; PMID:22349827; http://dx.doi.org/10.1038/onc.2012.33
42. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K. Stem cell marker (Nanog) and Stat- 3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012; 31: 149-60; PMID:21685938; http://dx.doi.org/10.1038/onc.2011.222
43. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-14; PMID:12717450; http://dx.doi.org/10.1038/nature01593
44. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, et al. Wnt proteins are lipidmodified and can act as stem cell growth factors. Nature 2003; 423: 448-52; PMID:12717451; http://dx.doi.org/10.1038/nature01611
45. Abrahams VM, Aldo PB, Murphy SP, Visintin I, Koga K, Wilson G, et al. TLR6 modulates first trimester trophoblast responses to peptidoglycan. J Immunol 2008; 180: 6035-43; PMID:18424724
46. Kim S, Karin M. Role of TLR2-dependent inflammation in metastatic progression. Ann N Y Acad Sci 2011; 1217: 191-206; PMID:21276007; http://dx.doi.org/10.1111/j.1749-6632.2010.05882.x
47. Wang Q, Dziarski R, Kirschning CJ, Muzio M, Gupta D. Micrococci and peptidoglycan activate TLR2->MyD88->IRAK->TRAF->NIK->IKK- ->NFkappaB signal transduction pathway that induces transcription of interleukin-8. Infect Immun 2001; 69: 2270-6; PMID:11254583; http://dx.doi.org/10.1128/IAI.69.4.2270-2276.2001
48. Yamashita YM, Fuller MT, Jones DL. Signaling in stem cell niches: lessons from the Drosophila germline. J Cell Sci 2005; 118: 665-72; PMID:15701923; http://dx.doi.org/10.1242/jcs.01680
49. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010; 29: 3545-53; PMID:20400975; http://dx.doi.org/10.1038/onc.2010.111
50. Luo JL, Kamata H, Karin M. IKK/NFkappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32; PMID:16200195; http://dx.doi.org/10.1172/JCI26322
51. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50; PMID:15229479; http://dx.doi.org/10.1038/nrc1388
52. Wu S, Lu X, Zhang ZL, Lei P, Hu P, Wang M, et al. CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2. Carcinogenesis 2011; 32: 296-304; PMID:21149644; http://dx.doi.org/10. 1093/carcin/bgq265
53. Yang HZ, Cui B, Liu HZ, Mi S, Yan J, Yan HM, et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 2009; 4:e6520; PMID:19654875; http://dx.doi.org/10.1371/journal. pone.0006520
54. Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 2002; 12: 454-8; PMID:12366662; http://dx.doi.org/10.1046/j.1525-1438.2002.01149.x
55. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61: 183-203; PMID:21521830; http://dx.doi.org/10.3322/caac.20113
56. Flick MB, O'Malley D, Rutherford T, Rodov S, Kamsteeg M, Hao XY, et al. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig 2004; 11: 252-9; PMID:15120700; http://dx.doi.org/10.1016/j. jsgi.2003.11.003
57. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003; 22: 2611-20; PMID:12730675; http://dx.doi.org/10. 1038/sj.onc.1206422
58. Green JM, Alvero AB, Kohen F, Mor G. 7-(O)-Carboxymethyl daidzein conjugated to N-t-Bochexylenediamine: a novel compound capable of inducing cell death in epithelial ovarian cancer stem cells. Cancer Biol Ther 2009; 8: 1747-53; PMID:19738422; http://dx.doi.org/10.4161/cbt.8.18.9285
59. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-72; PMID:18258665; http://dx.doi.org/10.1158/1078-0432.CCR-07-1569